Genmab Analyst Price Targets

Genmab AS

GMABNASDAQ

$33.45

0.040.12%

가까이에: Aug 21, 5:00 PM EST

$33.70

0.250.75%

시간외: Aug 21, 6:17 PM EST

Wall Street analyst price targets and consensus rating for Genmab (GMAB).

Price Target Range — 13 Quarters

Analyst Consensus — 13 Analysts

12Buy

1Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$39Upside to Avg. PT+16.3%

Rating Trend — Last 9 Months

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 7, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$40→$42
Jul 22, 2026	TD Cowen	Yaron Werber	Upgrade	Hold→Buy	$32→$43
Jul 2, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$38→$40
Jun 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$38
Apr 30, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$40→$38
Mar 27, 2026	Wolfe Research	Kalpit Patel	Initiate	Outperform	$32
Mar 2, 2026	Wells Fargo	Eva Fortea Verdejo	Initiate	Overweight	$40
Feb 23, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$45→$40
Feb 18, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$39→$40
Feb 17, 2026	Jefferies	Benjamin Jackson	Reinstates	Buy	$42
Feb 16, 2026	Morgan Stanley	Judah Frommer	Reinstates	Equal-Weight	$34
Jan 28, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$39
Jan 20, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$41→$39
Nov 10, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$40→$41
Nov 7, 2025	Truist Securities	Asthika Goonewardene	PT Cut	Buy	$49→$48
Oct 15, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$40
Oct 2, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$36→$40
Sep 24, 2025	Guggenheim	Michael Schmitz	Upgrade	Neutral→Buy	$43
Sep 23, 2025	Guggenheim	Michael Schmidt	Upgrade	Neutral→Buy	$43
Aug 15, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$35→$36